Quarterly report pursuant to Section 13 or 15(d)

Investment (Tables)

v3.22.0.1
Investment (Tables)
3 Months Ended
Dec. 31, 2021
Investment  
Schedule of carrying value of the Company's total investment in DepYmed

As of December 31,

As of September 30,

    

2021

    

2021

Carrying value of DepYmed common shares

$

$

Fair value of DepYmed preferred shares assumed in connection with acquisition of Ohr Pharmaceutical, Inc., a Delaware corporation that completed a Merger with NeuBase Therapeutics (“Ohr”)

 

 

99,020

DepYmed preferred shares received in sale of intellectual property

 

 

316,724

Total Investment

$

$

415,744